Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00947557 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin
A Phase 3 study, sponsored by Forest Laboratories.
- Terminated
- Registry status
- Phase 3
- Development phase
- 677
- Enrollment target
NCT00947557 is a Phase 3 study that was terminated before completion, run by Forest Laboratories. The registered enrollment target is 677 participants.
The verdict
NCT00947557, a Phase 3 study, was terminated before completion, sponsored by Forest Laboratories.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 677 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM) who are receiving background therapy of glimepiride with or without metformin.
Interventions
- DRUG Placebo
- DRUG Dutogliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 677 participants |
| Start Date | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00947557
The ClinicalTrials.gov registry entry for NCT00947557 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 677 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00947557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00947557 about?
NCT00947557 is a clinical study titled "Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin". This study will evaluate the safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM) who are receiving background therapy of glimepiride with or without metformin.
What is the current status of trial NCT00947557?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 677 participants. The study started on 2009-07.
What interventions are being tested in trial NCT00947557?
The interventions under investigation include: Placebo (DRUG), Dutogliptin (DRUG).
Who is sponsoring clinical trial NCT00947557?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.